LSD1-IN-27 manufacturers
- LSD1-IN-27
-
- $95.00
-
2026-07-15
- CAS:2904571-94-2
- Purity: 99.98%
- Supply Ability: 10g
|
| | LSD1-IN-27 Basic information |
| Product Name: | LSD1-IN-27 | | Synonyms: | LSD1-IN-27;1,4-Benzenediamine, N1,N1-dimethyl-N4-(2,5,6-trimethyl-9-acridinyl)-;N1,N1-Dimethyl-N4-(2,5,6-trimethylacridin-9-yl)benzene-1,4-diamine | | CAS: | 2904571-94-2 | | MF: | C24H25N3 | | MW: | 355.48 | | EINECS: | | | Product Categories: | | | Mol File: | 2904571-94-2.mol |  |
| | LSD1-IN-27 Chemical Properties |
| Boiling point | 533.1±50.0 °C(predicted) | | density | 1.170±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 9.61±0.10(predicted) | | form | Solid | | color | Yellow to orange |
| | LSD1-IN-27 Usage And Synthesis |
| Uses | LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer[1]. | | References | [1] Dai XJ, et al. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. Eur J Med Chem. 2023 Nov 5;259:115684. DOI:10.1016/j.ejmech.2023.115684 |
| | LSD1-IN-27 Preparation Products And Raw materials |
|